Biotechs boosted by Myners report on share issues
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.BIOTECHNOLOGY companies need more flexibility when they launch a rights issue to raise money on the London stock market, a Government- backed review found yesterday.
Paul Myners, the author of a series of reports on City finance, urged reform of the rules on pre-emption that give existing investors the power to block the creation of new shares. "I am calling for more flexibility and a move away from a blanket approach by the institutional investment community," he said.
UK companies must secure approval from existing investors before selling new stock worth more than 5 per cent of shares to other shareholders. The rules commonly affect loss-making, knowledge-based firms such as biotechnology companies when they try to raise money.
Companies planning rights offerings must file a prospectus and give shareholders at least 21 days to decide to accept the offer. In his 98-page report, Mr Myners said the Government and the Financial Services Authority watchdog should look at ways to shorten the process and reduce the documentation requirements.
Biotechnology companies such as Cambridge Antibody Technology Group and Antisoma told the review the current regime for rights issues was too expensive.
Yesterday the industry welcomed Mr Myners' findings. Aisling Burnand, the chief executive of the BioIndustry Association, said: "It is extremely positive that this important report has confirmed that there is an issue with the current pre-emption guidelines."
Lord Sainsbury, the Science Minister, said Mr Myners' recommendations would produce "a win-win situation" for companies and investors.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments